VigiCarib is a voluntary regional system for CARICOM states to report medicines related adverse events (adverse drug reactions (ADRs)) and substandard and falsified (SF) products. Medicines safety and monitoring systems are often limited in the individual small states of CARICOM, and the rationale for a regional approach is that with pooling of resources, sharing of information, and coordination of activities, there will be efficiencies of scale that can lead to stronger systems overall.
Supporting Global Vigilance and Post-market Surveillance:
VigiCarib network facilitates the submission of reports of suspected adverse drug reactions (ADRs), and reports of quality issues to international monitoring systems of the WHO Programme for International Drug Monitoring at Uppsala Monitoring Centre, and to the WHO Global Surveillance and Monitoring System. This assists Member States with limited human resources to contribute to global vigilance, and to receive information on international and regional trends in reporting.
Reports of suspected adverse drug reactions, and reports of suspect substandard / falsified / unregistered medicines may be submitted confidentially to VigiCarib using any of the following methods:
The VigiCarib Reporting form in Word;
The VigiCarib Online Form at: https://form.jotform.co/72934157245864; or
E-Reporting (for reports of suspected adverse drug reactions from St Vincent and the Grenadines): https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=VC
Pharmacovigilance in Member States:
Additional information on pharmacovigilance and post-market surveillance in some Member States may be found at the following sites:
Collaboration with MQCSD:
The CRS works in collaboration with the Medicines Quality Control and Surveillance Department (here
) in its post-market surveillance functions. Through the VigiCarib network reports of substandard and/or falsified medicines identified in Member States are shared with the MQCSD, and focal points are encouraged to contact the department for information on testing. In addition, when products are found to be substandard or falsified when tested by the MQCSD, the Member State is encouraged to share this in the network.